Compound ID | 55

Update compound information

LTX-109

Synonym(s): AMC-109  |  lytixar  |  Voxvoganan

Class: Antimicrobial peptidomimetic

Spectrum of activity: Gram-positive
Details of activity: Topical treatment of skin infections and nasal eradication of staphylococcus, regardless of resistance.
Propensity to select resistant mutants: Yes
Description: Synthetic compound
Institute where first reported: Lytix Biopharma, Norway
Year first mentioned: 2008
Highest developmental phase: Phase 2
Development status: Active (as of 2024)
Chemical structure(s):
Click here for structure editor
Molecular weight: 788.08
Iso. SMILES: CC(C)(C)C1=CC2=C(C(=C1)C(C)(C)C)NC(=C2C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCCC3=CC=CC=C3)NC(=O)[C@H](CCCN=C(N)N)N)C(C)(C)C
InChI Key: ZVOYWSKEBVVLGW-ZDCRTTOTSA-N
Can. SMILES: CC(C)(C)C1=CC2=C(C(=C1)C(C)(C)C)NC(=C2C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCCC3=CC=CC=C3)NC(=O)[C@H](CCCN=C(N)N)N)C(C)(C)C
InChI: InChI=1S/C43H69N11O3/c1-41(2,3)27-23-28-29(35(43(7,8)9)54-34(28)30(24-27)42(4,5)6)25-33(53-36(55)31(44)17-13-20-50-39(45)46)38(57)52-32(18-14-21-51-40(47)48)37(56)49-22-19-26-15-11-10-12-16-26/h10-12,15-16,23-24,31-33,54H,13-14,17-22,25,44H2,1-9H3,(H,49,56)(H,52,57)(H,53,55)(H4,45,46,50)(H4,47,48,51)/t31-,32-,33-/m0/s1
External links:
PubChem link: https://pubchem.ncbi.nlm.nih.gov/compound/25242323
Guide to Pharmacology: voxvoganan
Citations:
  • https://idsa.confex.com/idsa/2008/webprogram/Paper26744.html
  • http://www.lytixbiopharma.com/news/162/130/Lytix-Biopharma-presented-new-data-on-antimicrobial-drug-LytixarTM-LTX-109-at-ICAAC.html
  • http://www.lytixbiopharma.com/uploads/A2_030_Lytix_Biopharma_poster_96x48inch.pdf
  • https://journals.asm.org/doi/full/10.1128/aac.03513-14?rfr_dat=cr_pub++0pubmed&url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org

    • AntibioticDB is supported by GARDP.

    If you have feedback, experience problems, or are interested in a collaboration, please contact us. | Terms and conditions

    The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.